# A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder

> **NCT00966004** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 1139 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** YM178
- **DRUG:** Placebo
- **DRUG:** tolterodine

## Key facts

- **NCT ID:** NCT00966004
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-24
- **Primary completion:** 2010-02-15
- **Final completion:** 2010-02-15
- **Target enrollment:** 1139 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00966004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00966004, "A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00966004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*